Director sold ~$172K of Dexcom
Scheduled in advanceTraded Nov 12, 2025 · Filed Nov 12, 2025
A board member of Dexcom sold $59K of Dexcom shares. It was planned long ago, so it says very little.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$58,767
Shares × reported transaction price
13 days after results of Oct 30, 2025, 61 days before results of Jan 12, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $59.61 on Nov 12, 2025, 9% above its 52-week low and 34% below its high, after a 10% drop over the previous 30 trading days
52-week range $54.84 (Nov 10, 2025) to $90.75 (Feb 24, 2025), 13% of the way up, from 250 adjusted closes. 30 trading days earlier: $66.08 on Oct 1, 2025. Describes the past only, not a forecast
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
A securities lawsuit naming the company as a defendant was filed on Nov 10, 2025 in the U.S. District Court, S.D. New York. A filing is an allegation, not a finding.
5 such cases were open. Oakland County Employees Retirement System v. DexCom, Inc., docket 1:25-cv-09370, via CourtListener (court records). Nature of suit 850, company named as first defendant
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | -2.2% | -2.9% | +0.7% |
| 30 days | +10.1% | +1.3% | +8.8% |
| 90 days | +14.1% | +3.0% | +11.2% |
| 180 days | +2.4% | +9.8% | -7.5% |
Past results only. Not a forecast.
Director sold ~$172K of Dexcom
Scheduled in advance313K → 329K shares held+5% of their stake
Dexcom's President & COO spent $863K of their very own money to buy Dexcom shares. Their pile of Dexcom shares grew by 5%.
329K → 332K shares held+1% of their stake
Dexcom's President & COO spent $139K of their very own money to buy Dexcom shares.